Ron-Guerrero CS, Ron-Magaña AL, Medina-Palacios CL, López-Flores F

Language: Spanish
References: 14
Page: 109-114
PDF size: 520.71 Kb.

ABSTRACT

Background: Lymphomas are a heterogeneous group of malignancies, its incidence has increased from 2-3% in recent decades worldwide. The molecular and immuno-genetic development has a positive impact on the classification and prognosis of these diseases.
Objective: To describe and analyze the epidemiological trend of lymphoma patients treated at the Cancer Center of State Health Services of Nayarit, Mexico.
Material and method: A retrospective and analytical study in which records of lymphoma patients were reviewed from January 2011 to December 2014 and data were summarized using measures of central tendency, standard deviation and percentages, and also the survival of patients and the cumulative mortality were calculated with the method of Kaplan and Meier.
Results: Eighty-one cases with lymphoma, incidence of 3.4/100,000/year; 39 were males. Diffuse large B-cell lymphoma was the most common (n=30). The average age with standard deviation for both genders was 57.8 ± 15.6 years, corresponding to women 59.3 ± 16.18 years and for men 55.51 ± 14.54 years. Regarding the diffuse large B-cell lymphoma (DLBCL), there was slight predominance in males (16/30), average age of 57.7 ± 12.9 years, as women (14/30), average age of 56.2 ± 17.2 years. Disease-free survival at 60 months was estimated of 70% .
Conclusions: Lymphomas are presented at the same frequency as that reported in the literature; however, in our study they were more common in women. The middle ages are also slightly younger in both genders. Survival and cure were the same as reported in the literature, when rituximab is used.

REFERENCES

1. Jamal A. Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.

2. KnowlesDM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12:200-217.

3. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development autoimmune diseases: a metaanalysis. Arch Intern Med 2005;165:2337-2344.

4. Dohden K, Kaiszaki Y, Hosokawa O, et al. Regression of rectal mucosa-associated lymphoid tissue lymphoma but persistence of Helicobacter pylori infection of gastric mucosa after administration of levofloxacin: report a case. Dis Colon Rectum 2004;47:1544-1546.

5. Engels EA, Chatterjee N, Cerhan JR, Davis S, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of NCI-SEER multi-center case-control study. Int J Cancer 2004;111:76-80.

6. Savage Kl, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533-3537.

7. Coiffier B, Thieblemontc C, Vardan E, et al. Longterm outcome of patients of NLH-98-5 trial. Blood 2010;116:2040-2045.

8. Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest 2008;26:306-316.

9. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63:11-30.

10. Globocan 2008http://www-dep.iarc.fr.

11. American Cancer Society. Cancer & Figures 2015. Atlanta, Ga: American Cancer Society 2015.

12. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276.

13. Labardini-Méndez J, Cervera-Ceballos E, Corrales-Alfaro C y col. Linfoma no Hodgkin Onco-guía. Cancerología 2001;6:139-152.

14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cel lymphoma. N Engl J Med 2002;346:235-242.